US 11,913,954 B2
Combination treponemal and non-treponemal syphilis test
Ravi Kaul, Davis, CA (US); Weiming Zheng, Emeryville, CA (US); and Roger Walker, Benicia, CA (US)
Assigned to Bio-Rad Laboratories, Inc., Hercules, CA (US)
Filed by Bio-Rad Laboratories, Inc., Hercules, CA (US)
Filed on Feb. 8, 2021, as Appl. No. 17/170,577.
Application 16/832,608 is a division of application No. 16/405,588, filed on May 7, 2019, granted, now 10,648,981, issued on May 12, 2020.
Application 17/170,577 is a continuation of application No. 16/832,608, filed on Mar. 27, 2020, granted, now 10,942,182.
Application 16/405,588 is a continuation of application No. 15/701,272, filed on Sep. 11, 2017, granted, now 10,324,091, issued on Jun. 18, 2019.
Application 15/701,272 is a continuation of application No. PCT/US2016/021379, filed on Mar. 8, 2016.
Claims priority of provisional application 62/181,685, filed on Jun. 18, 2015.
Claims priority of provisional application 62/131,062, filed on Mar. 10, 2015.
Prior Publication US 2021/0156859 A1, May 27, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/53 (2006.01); G01N 33/571 (2006.01); G01N 33/543 (2006.01); G01N 33/92 (2006.01)
CPC G01N 33/571 (2013.01) [G01N 33/543 (2013.01); G01N 33/54313 (2013.01); G01N 33/92 (2013.01); G01N 2333/20 (2013.01); G01N 2405/04 (2013.01); G01N 2469/20 (2013.01)] 15 Claims
 
1. A method of detecting the presence of syphilis antibodies in a sample comprising:
(a) contacting the sample with (i) a cardiolipin-lecithin-cholesterol antigen non-covalently attached to a solid support, wherein the cardiolipin-lecithin-cholesterol antigen is unmodified to reduce hydrophobicity; and (ii) a Treponema pallidum antigen attached to a solid support;
(b) washing the solid supports of (i) and (ii) to remove unbound sample;
(c) contacting the solid supports of (i) and (ii) with a labeled, anti-human immunoglobulin (Ig) antibody; and
(d) detecting the presence of syphilis antibodies by detecting the label on the anti- human Ig antibody.